AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 271 min read

Oppenheimer initiates coverage of PolyPid with Outperform rating, $10 price target

Oppenheimer initiated coverage of PolyPid with an Outperform rating and $10 price target, implying 89% upside. The company's lead product, D-PLEX100, showed 60% efficacy in reducing SSIs, with FDA Priority Review. PolyPid has a partnership with Azurity for commercialization, with a potential 2027 launch.

Original reporting
tradingview.com
Published Oct 27, 2026, 3:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 3:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Oppenheimer initiates coverage of PolyPid with Outperform rating, $10 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

High
01

Why it matters

The coverage is expected to generate buying interest and lift the stock toward the $10 target.

02

Market read

New analyst rating and price target provide a clear actionable signal for traders, especially given the significant upside potential.

03

What to watch

Commercialization risk with partner Azurity and execution of the launch timeline.

Relevance 8/10Novelty 9/10Timing: immediate

Background

Analyst initiation with a new price target and rating based on fresh Phase 3 trial results and regulatory progress.

Market effects

Sector

Positive clinical data and FDA priority review may lift sentiment across the biotech sector.

Regional

US biotech stocks could see short‑term buying pressure.

Global

May influence global biotech valuations and partner companies.

Counterpoint

What could challenge this read

Risk of FDA delay or adverse review could negate the upside.

Key entities

  • company
    PolyPid Therapeutics

    Biotech firm developing D‑PLEX100 for surgical‑site infection prevention.

  • analyst
    Oppenheimer

    Investment bank that initiated coverage with an Outperform rating.

Read at source← All news

StoryOppenheimer initiates coverage of PolyPid with Outperform rating and $10 price target

Related articles

OCT 27
$PYPDHighAI 8/10

Oppenheimer initiates PolyPid stock coverage with outperform rating

Oppenheimer initiated coverage on PolyPid (NASDAQ:PYPD) with an outperform rating and a $10.00 price target. The stock is up 47% over the past year, with a Strong Buy consensus and targets ranging from $8 to $14. PolyPid's D-PLEX100 reduced surgical site infections by 60% in a Phase 3 study and is under FDA Priority Review. The company reported a narrower Q2 2026 loss of $0.35 per share, beating expectations.

investing.com2 min
OCT 9
$PYPDMed

What PolyPid’s Bold Moves in Europe Could Mean for D-PLEX₁₀₀’s Global Potential (NASDAQ: PYPD) By FinanceWire

PolyPid (NASDAQ: PYPD) announced European Medicines Agency validation of its D-PLEX₁₀₀ Marketing Authorization Application and regained full European commercialization rights. The company's stock rose 15% premarket. D-PLEX₁₀₀, a surgical site infection treatment, has positive Phase 3 data and FDA Priority Review in the U.S. PolyPid aims to partner in Europe on stronger terms than its previous agreement.

investing.com2 min
OCT 1
$PYPDHighAI 8/10

European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀

PolyPid's (PYPD) Marketing Authorization Application for D-PLEX₁₀₀, a drug to prevent post-abdominal surgery infections, has been validated by the European Medicines Agency. The application is now under formal review. The FDA is also reviewing D-PLEX₁₀₀ under Priority Review with a PDUFA goal date of November 28, 2026. The drug showed a 60% relative risk reduction in surgical site infections in a Phase 3 trial.

globenewswire.com2 min